Black Diamond Therapeutics, Inc. Balance Sheet
BDTX|2 years of annual SEC 10-K data (FY2019-FY2020)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$330M
FY2020
Cash
$35M
Cash and equivalents
Total Debt
N/A
FY2020
Shareholder Equity
$308M
FY2020
Black Diamond Therapeutics, Inc. had $330M in total assets and $308M in shareholders' equity as of FY2020.
Based on SEC 10-K filings.
Key Data Points
- Piotroski F-Score: 2/9 criteria passed
- Altman Z-Score 5.60 (safe zone, above 2.9 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -21.9% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2019 |
|---|---|---|
| Cash & Equivalents | $34.6M | $154.7M |
| Current Assets | $319.6M | $155.7M |
| PP&E (Net) | $385.0K | $164.0K |
| Total Assets | $329.7M | $158.3M |
| Current Liabilities | $14.2M | $4.9M |
| Shareholders' Equity | $307.8M | -$47.2M |